Real-Time Whole Slide Pathology Image Cell Counting
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2019/013700, filed Jan 15, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,406,366 | Real-Time Whole Slide Pathology Image Cell Counting In force · Medium confidence UsedRemaining | Nantomics, LLC | In force | Medium confidence | ||
| US 11,954,856 | Real-Time Whole Slide Pathology Image Cell Counting In force · Medium confidence | Nantomics, LLC | In force | Medium confidence | ||
| US 11,443,426 | Real-Time Whole Slide Pathology Image Cell Counting In force · High confidence | Nantomics, LLC | In force | High confidence | ||
| Application 19/256,651 | Real-Time Whole Slide Pathology Image Cell Counting Pending Not granted | NantOmics, LLC | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Nantomics, LLC.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.